biggest twitch female streamers

biggest twitch female streamers Kindle Paperwhite SE: One-minute review The Amazon Kindle Paperwhite is a mainstay on our list of the best Kindles , and the new Paperwhite offers just enough improvements to keep the e-reader feeling fresh while still leaving me wanting a bit more. It’s a little brighter, a little sharper, and a lot faster, and it turns out that speed truly makes a difference if you read a lot. The main factor behind your choice of e-reader is where you get your books. If you buy books from Amazon or subscribe to Amazon’s Kindle Unlimited service, the Kindle is your only choice, and the Kindle Paperwhite is the best Kindle for most people. It’s bright, durable, and even water-resistant enough to survive a splash of salt water if you want to read in the sand. Of course, the color Kindle is here, but don’t look at the Kindle Colorsoft if you don’t yearn for color when you read. It’s hard to go back to black and white once you’ve seen it, and the Colorsoft costs a lot more than the Kindle Paperwhite. That’s fine because the Kindle Paperwhite does everything you’d expect from a Kindle, no more and no less. If you want a bit more, my review sample was the Kindle Paperwhite Signature Edition, which includes wireless charging and maxes out the storage. I didn’t once charge the Kindle wirelessly except to test that it works, but you can buy a dock from Amazon to prop your Kindle at your bedside and let it charge while it shows you the cover of the book you’re reading. That’s if you pay a little extra for the Kindle Paperwhite without lockscreen ads. I’m not a fan of Amazon’s common lockscreen ad scheme. I don’t like my phone, tablet, or e-reader serving me ads as a privilege of ownership. It feels cynical, and even though you can save $20 / £10 (and why is it so much cheaper in the UK?!) by allowing Amazon to take over your Kindle lockscreen with advertisements, I’d rather see my book covers or even just Amazon’s pleasant reading-themed wallpapers. Thankfully, the Signature Edition doesn't have lockscreen ads. If you get your books from the library (yes, your local library will lend you an e-book) or if you buy from a seller other than Amazon, you have more choices, but the Kindle Paperwhite is still one of the best. I wish it had real buttons to turn pages, like the Kobo Libra e-reader. Buttons just feel more reliable than tapping or swiping, especially if I’m in the tub and my fingers are soapy. The Kindle Paperwhite Signature Edition exceeds other e-readers in its speed and responsiveness. Turning pages feels fast now, much faster than it was on older Kindle devices, and zooming into a chart or a picture happens almost as quickly as it would on a smartphone. I didn’t think a performance boost would make such a huge difference for a Kindle, but it’s really noticeable and makes the e-reader better. Besides the library, Amazon’s Kindle book store is also the most robust place to buy books. You’ll find every title you want, and the store is great at making suggestions. I was slightly disappointed by the Kindle Unlimited content offering, though, so I wouldn’t recommend the subscription service unless reading is your passion and not just a pastime. The new Kindle Paperwhite is an easy e-reader to recommend because the Paperwhite wasn’t broken, and Amazon didn’t fix it. It’s just a bit better, but it does everything I need an electronic book to do. The only thing I miss is color, and I suspect that the next Paperwhite upgrade that comes along in a few years will satisfy that craving. Kindle Paperwhite SE review: price and availability $159.99 / £159.99 for the Kindle Paperwhite with 16GB of storage, with ads $199.99 / £189.99 for the Signature Edition with 32GB and wireless charging No Australia launch date yet The Kindle Paperwhite and Paperwhite Signature Edition are a bit more expensive than the Kindle Paperwhite from 2021 , and you don’t really get anything new. It’s a better device, to be sure, with a brighter screen and a more responsive interface, but I don’t like that it’s creeping up in price, especially since it’s an excellent vessel for Amazon to sell you more Kindle books. Never fear! Because the Kindle Paperwhite will likely get discounted often. I’m finishing this review just before the 2024 Black Friday deals season starts, and the Kindle Paperwhite Signature Edition already has its first discount: it’s $45 / £35 off at Amazon . That’s a good start! I’m sure we’ll see this e-reader drop in price every time Amazon has a sale day, or a holiday, or a day that ends in 'y.' Is it worth the price? Compared to what? There aren’t any other e-readers that synchronize perfectly with Amazon’s book store, unless you buy a more expensive device that runs Android and can load the Kindle app. That’s a bridge too far, on my reading journey. You can find a Kobo Clara e-reader with a smaller display for less money; you can even get a Kobo Clara Color e-reader for less than a Kindle Paperwhite, let alone the Signature Edition Paperwhite. The Clara has a smaller display, and you should definitely explore Kobo’s book library before you commit if you’re making a switch. Value score: 4 / 5 Kindle Paperwhite SE review: Specs Kindle Paperwhite SE review: design Looks nicer with Signature Edition metallic paint No page turning buttons, and power button is poorly placed The Amazon Kindle Paperwhite is a very simple e-reader, and Amazon hasn’t improved the design at all except to offer some brighter paint options, especially if you spring for the Signature Edition with its metallic paint. That’s the review sample I have, and I like the look much more than the basic matte black finish, as you’ll find on the Paperwhite and the Kindle Colorsoft. What happened to Kindles that felt premium? The Kindle Oasis lingered for years as a premium model, clad in metal with real page-turn buttons. I guess Amazon gave that all up to cut prices, or maybe readers just didn’t want to pay more for a luxurious electronic book. In any case, I hope Amazon offers an alternative to the bland plastic Kindle Paperwhite slab in the future. I also hope Amazon brings back page buttons because pressing a button is easier than swiping or tapping on the correct spot. If I held the Kindle Paperwhite SE too high, I’d open a menu instead of turning the page. Just give me a button. There's only one button on the Kindle Paperwhite SE, and it’s the unfortunately placed power button. If you rest the Paperwhite on a desk while reading or rest it heavily on a finger for balance, you might turn off the screen by accident. The Kindle Paperwhite Signature Edition is certainly simple; I just wish there were more elegance to be found. Design score: 2 / 5 Kindle Paperwhite SE review: display E Ink Carta 1300 display Full set of white and amber LEDs for reading at night The Amazon Kindle Paperwhite Signature Edition uses the latest E Ink black and white Carta 1300 display, which doesn’t offer more sharpness than past Kindle screens, but the Kindle already looks great when it’s displaying text and writing. Pictures look good enough in 16 levels of grey, but if you want better graphics, you should go for the Kindle Colorsoft. The display does an impressive job keeping up with the improved performance inside. I expected to see a lot more ghosting and residual characters as I zoomed in and out of a page, but the Paperwhite SE gave me a lighter version of my screen for panning, then flashed briefly and gave me a darker, final version when I was steady. The Kindle Paperwhite SE can get plenty bright, so be warned that the incredible 12 weeks of battery life only applies when you are reading at half brightness. If you are in a well-lit room you won’t need any light at all, but reading before bed is my personal habit, so I use the light frequently. There’s a full set of amber lights and white LEDs inside so that you can eliminate all the blue light before bedtime. Display score: 4 / 5 Kindle Paperwhite SE review: software Amazon’s Kindle software keeps things very simple Better performance makes menus and libraries move faster If you buy books through Amazon, the Kindle Paperwhite Signature Edition does a perfect job delivering those books to your device. The Kindle can synchronize your progress easily if you read across multiple devices. It can also report your reading to Goodreads automatically or connect you to the social service to write your own reviews. There isn’t much more to the Kindle Paperwhite SE. If you have books from other sources, you can connect the Kindle Paperwhite to your computer directly or just synchronize through Amazon’s web-based software. There is a web browser, but it’s dreadfully simple, maybe thankfully so. You won’t find yourself distracted and browsing your favorite websites on this e-reader. I could barely get TechRadar.com to load beyond some text boxes. The big thing that I’m missing with Kindle software is the ability to annotate my books right on the page. The Kobo Libra can use a stylus to take notes on a book. Not just highlighting or sticky notes but actually drawing in the margins and on the page. It’s a nifty trick that Amazon really needs to adopt, especially for the Kindle Scribe . User experience score: 4 / 5 Kindle Paperwhite SE review: performance Surprisingly fast performance on E Ink Improved scrolling, moves faster than before Amazon gave the Kindle Paperwhite Signature Edition a dual-core processor inside, which makes this electronic book more powerful than the Apollo 11 lunar lander. That means it can turn pages very quickly. I joke, but in fact, the difference is noticeable if you’ve ever owned a Kindle and been annoyed by slow page turns. The only place where the Kindle still lags behind modern technology is in touch sensitivity. The E Ink display is not very sensitive, and I still felt a delay between tapping the screen, like when I needed to enter my Wi-Fi password, and when the character appeared. Menus were faster when I was scrolling, but still not totally reliable when tapping through them. Frankly, there’s not much more I could ask for with Kindle performance. I’ve seen E Ink displays that try to do a lot more, and they overcomplicate simple technology like e-paper. I’m happy that Amazon made the interface more responsive. The next frontier is touch response. Performance score: 4 / 5 Kindle Paperwhite SE review: battery Excellent battery life, if you follow the rules Avid readers will get a week of battery life or more The Kindle Paperwhite Signature Edition will last for 12 weeks on a single charge, if you’re a casual reader. Amazon’s 12-week claim calls for 30 minutes of reading with the screen at just under half brightness. If you read all day in bright sunshine, the Kindle Paperwhite SE might last longer. If you read in the dark New England winter nights, the Paperwhite will need to charge more often. The good news is that you will get over 40 hours of screen time between charges, and the battery won’t die if you put the book down for a few weeks. If you read at a good pace, you’ll be able to read a couple of books before you need to charge the Kindle Paperwhite, and that’s exceptional for any modern electronic device. The Kindle Paperwhite Signature Edition features wireless charging. I like the wireless option as an elegant solution for keeping your Kindle topped up on a bedside stand, but it’s not essential at all. Battery score: 5 / 5 Should I buy the Kindle Paperwhite Signature Edition? Buy it if... You want a new Kindle Amazon hasn’t given us a proper new Kindle for reading in years. Time to rejoice! New Kindles have arrived. You’re a serious reader You can buy the cheaper Amazon Kindle, but serious readers want brighter displays with better battery life, and the Paperwhite is the one. You’ll be reading in harsh, beach-like conditions The Kindle Paperwhite is IP67 rated, so it can resist sand and even salt-water (with a proper rinse after). Don't buy it if... You read comics or graphic novels If you don’t care about color, don’t worry about the Kindle Colorsoft. But who doesn’t care about color?! You want to take notes on your books E-readers from Kobo can write directly on the pages, and there’s always the Kindle Scribe if you need a pen. You expect a real web browser The Amazon Kindle Paperwhite still keeps things simple. This device is for reading without distractions, not doomscrolling. Also consider Kobo Clara Colour You can save a bit of money and even check out a color E Ink display with the Kobo Clara Color. As long as your books aren’t all on Kindle, it’s worth a look. Read our in-depth Kobo Clara Color review Amazon Kindle Paperwhite (2024) The base model Kindle Paperwhite doesn't have wireless charging, which I never needed, and it comes with only 16GB of storage, which is more than enough for most avid readers. Check out the Kindle Paperwhite at Amazon How I tested the Amazon Kindle Colorsoft Signature Edition Testing period - three weeks Subscribed to Kindle Unlimited and Comixology Tested books, comics, audiobooks, and bathtub reading I used the Amazon Kindle Paperwhite Signature Edition for three weeks before I published this review. I read two novels, multiple short stories, Japanese manga, and a number of other materials, including cookbooks and magazine. I used the Kindle Paperwhite Signature Edition for listening to audiobooks from Audible, and for listening while I read the same book. I used the Paperwhite in the bathtub to test its water resistance, and because reading in the bathtub is the main reason I like to review Kindle Paperwhite devices. I did not have a dedicated wireless charging dock, but I tried charging the Kindle Paperwhite Signature Edition with a Qi-compatible wireless charging adapter that attaches magnetically to the back of a smartphone. Before my review period I charged the Kindle Paperwhite Signature Edition using the USB-C port, and I only charged it one more time before this review was completed, even though I read daily and usually for more than an hour a day. I used the Kindle Paperwhite without a case, and the photos in this review reflect its condition after daily use without a case, which is pretty good. I subscribed to Amazon’s Kindle Unlimited service and Comixology, and I also loaded books into my collection through the Overdrive library borrowing system and my local library. Read more about how we test [ First reviewed November 2024 ]

‘I’m exhausted:’ Miami basketball coach Jim Larrañaga resigns, citing new NIL challenges

Teen actor Hudson Meek, best known for his role in the hit action movie “Baby Driver,” has died at 16 years old. Meek sustained blunt force trauma in the fall on Dec. 19 and was admitted to the University of Alabama at Birmingham Hospital, where he succumbed to his injuries. “His 16 years on this earth were far too short, but he accomplished so much and significantly impacted everyone he met.” Tributes began pouring in across social media from those who knew Meek and worked with him. “Hudson Meek was a beloved and talented member of the Acting Out Academy community since the beginning. But that is just one piece of the magical person that he was. He was kind, he was faithful, he was funny and lit up any room. He touched so many lives and will be missed beyond measure,” Deusner said. He made his on-screen debut in 2014’s “The Santa Con” and held various acting and voice-over credits over his short yet well-established career. His obituary states Meek worked on several major motion pictures and television shows before his passing, some of which will be released in 2025. “He absolutely loved spending time on set and having the chance to learn the names and stories of every member of the cast and crew,” it reads. Meek is survived by his parents, older brother, and grandmothers. A Celebration of Life will take place on Dec. 28, at Dawson Memorial Baptist Church in Homewood, Alabama, with the service being livestreamed on Meek’s Instagram account.Click celebrates significant growth milestones while introducing a new initiative to support and empower photojournalists in sharing authentic, impactful stories through the platform. SAN FRANCISCO , Dec. 11, 2024 /PRNewswire/ -- Click , a groundbreaking mobile app that fights misinformation by making it simple to capture and publish authenticated content, powered by the Nodle Network , has recently launched the Click Photojournalism Fellowship, to empower photojournalists to join Click's mission to build a more truthful future. Joining the fellowship will give photojournalists exposure of their work via the Click app and Nodle Network and allow each photojournalist to share their stories and their photos. Additionally, Click has just reached two growth milestones in its first year of operation, passing 50,000 users and over 1,000 new photos authenticated by Click daily. These follow Click's public beta launch in March. The Click camera app is currently available for download on both iOS or Android , and all content captured with Click can be accessed through the app and on Click's website at clickapp.com . The first two photojournalists to join the Click Fellowship are: "We're thrilled to collaborate with photojournalists, empowering them to share their authentic stories through Click. In an era where digital content authenticity is crucial, we're leveraging blockchain to support journalists in building transparency and trust. The Click Photojournalism Fellowship sets a new standard for credibility in journalistic content on social media," says Micha Benoliel , CEO and co-founder of Intergalactic Labs, the team behind Click and Nodle. Click aims to grow the fellowship to over 20 photojournalists in early 2025 and is currently seeking more photojournalist partners. Photojournalists who join the program will share their recent work via Click's blog (both Click and non-Click photos), that represent their photojournalistic perspective, share their journalist story and be promoted across the Click and Nodle communities. Journalists will also provide feedback on the Click app periodically via scheduled sessions with Click's team. To apply and join the fellowship, photojournalists can fill out this short application and share samples of their work. About Click: Click is a new mobile app empowering everyone to easily create authentic media content. Click is on a mission to combat misinformation and bring truthful photos and videos aka "Deep Reals" to everyone via immutable digital proofs of authenticity. With Click, you can confirm content is real and happened at a specific location, time and via a specific mobile device and camera. This is all made possible by ContentSign , Click's proprietary technology which proves the integrity of data from its moment of capture on-chain. Click is built on ZKsync , the leading Ethereum Layer 2 blockchain and is powered by the Nodle DePIN. Click supports the Coalition for Content Provenance and Authenticity (C2PA) and is a member of the Adobe-led Content Authenticity Initiative (CAI). Download Click on iOS or Android and visit us at clickapp.com to learn more and see recent press coverage. View original content to download multimedia: https://www.prnewswire.com/news-releases/click-camera-app-announces-new-photojournalism-fellowship-as-app-reaches-50-000-users-signing-1-000-authenticated-photos-daily-302329583.html SOURCE Nodle

FLORENCE, Italy & BARCELONA, Spain--(BUSINESS WIRE)--Dec 11, 2024-- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with MEDSIR, a leading global independent clinical research company in oncology and part of Oncoclínicas & Co., the largest specialized oncology treatment group in Latin America, presented research on the pioneering clinical trial ADELA. This important research addresses therapeutic resistance in advanced ER+/HER2- breast cancer. Presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), the study represents a key milestone in the quest for more effective and personalized treatment options for patients with disease progression. The standard first-line treatment for advanced ER+/HER2- breast cancer combines endocrine therapy with CDK4/6 inhibitors. ESR1 mutations develop as a result of prior exposure to endocrine therapy during metastatic treatment, and up to 50% of ER+, HER2- advanced or metastatic breast cancers will develop these mutations. ESR1 mutations cause the tumors to become resistant to endocrine therapy, in turn causing the cancer to progress; therefore, it is important to test for ESR1 whenever mBC progresses. Longer exposure to endocrine therapy during first-line treatment increases the chance of a patient’s tumor developing an ESR1 mutation. With the goal of addressing this unmet medical need, the ADELA phase III clinical trial investigates a new therapeutic option combining elacestrant, a next generation, oral selective estrogen receptor degrader, with everolimus, an mTORC1 inhibitor. This combination is being evaluated in patients with advanced ER+/HER2- breast cancer that harbors ESR1 mutations, and who have experienced progression after standard first-line treatment. Results from the phase III EMERALD study were the basis for elacestrant’s approval. Meanwhile, everolimus has shown efficacy in inhibiting other resistance mechanisms in this type of cancer. The elacestrant and everolimus combination has demonstrated preliminary efficacy with a manageable safety profile in the phase 1b/2 ELEVATE study ( NCT05563220 ). “We at Menarini Stemline are delighted to announce the collaboration with MEDSIR to continue advancing the clinical research to explore the combination therapy with elacestrant,” said Nassir Habboubi, MD, Chief Medical Officer of Stemline Therapeutics. “We are committed to driving innovation in cancer treatment by delivering transformational therapies aiming to extend the lives of people living with cancer.” The primary objective of this international, randomized, double-blind trial is to evaluate whether the combination of elacestrant and everolimus offers greater efficacy in delaying disease progression compared to elacestrant monotherapy. Additionally, it investigates other crucial aspects, such as overall survival, toxicity profile, and the impact on patients’ quality of life. The ADELA study represents a critical step in understanding how to overcome tumor resistance challenges in patients with ESR1 mutations, with the goal of advancing towards more effective and safer treatments. “At MEDSIR, we understand innovation not only as achieving clinical results but as the ability to transform patients' lives on a global scale. With ADELA, we take a decisive step toward accomplishing less invasive and more accessible treatments, aiming to offer new hope to those facing the most complex forms of the disease. This advancement reinforces our commitment to increasingly personalized and patient-centered medicine, a fundamental pillar in shaping the future of oncology,” said Dr. Antonio Llombart-Cussac, Senior Scientific Leader at MEDSIR. The phase III study not only has significant clinical objectives, but also holds the potential to pave the way for regulatory approval of this therapeutic combination, enabling its use in a broader population of patients with advanced breast cancer. Moreover, the international scope of the study, which includes participation from multiple countries, including Spain, Italy, France, Austria, the Czech Republic, Greece, Germany, and the United Kingdom, underscores the study’s global importance and relevance in the scientific community. The presentation of the ADELA study at an event as prominent as SABCS 2024 reinforces MEDSIR’s leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in breast cancer treatment. The ADELA study is active and already recruiting patients. About ORSERDU (elacestrant) U.S. Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Full prescribing information for the U.S. can be found at www.orserdu.com . Important Safety Information Warning and Precautions Dyslipidemia : Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively. Monitor lipid profile prior to starting and periodically while taking ORSERDU. Embryo-Fetal Toxicity : Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose. Adverse Reactions Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). The most common adverse reactions (≥10%) , including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%). Drug interactions Concomitant use with CYP3A4 Inducers and/or inhibitors : Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU. Use in specific populations Lactation : Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose. Hepatic Impairment : Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B). The safety and effectiveness of ORSERDU in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . About The Menarini Group The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com . About Stemline Therapeutics Inc. Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU ® (elacestrant) in the U.S. and Europe, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS ® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the U.S. and E.U. to date. Stemline also commercializes NEXPOVIO ® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers. About MEDSIR Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials. With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: www.medsir.org About Oncoclínicas & CO Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a specialized and innovative model focused on the entire oncology care journey, combining operational efficiency, humanized care, and high specialization through a medical team composed of over 2,700 specialist physicians with an emphasis on oncology. With its mission to democratize cancer treatment, it offers a comprehensive system that integrates outpatient clinics with high-complexity cancer centers. The company operates 145 units across 39 Brazilian cities, allowing high-quality access in all regions it serves, aligned with world-class standards. Focusing on technology, precision medicine, and genomics, Oncoclínicas performed approximately 635,000 treatments in 2023. It is the exclusive partner in Brazil of the Dana Farber Cancer Institute, affiliated with Harvard Medical School, one of the world’s leading cancer research and treatments centers. The company also owns Boston Lighthouse Innovation, a bioinformatics firm based in Cambridge, United States, and holds shares in Medsir, a company dedicated to the development and management of clinical trials for independent cancer research, based in Barcelona, Spain. Recently, Oncoclínicas expanded its operations to Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its mission to beat cancer to a new continent and providing advanced oncology care on a global scale by combining oncological hyperspecialization with innovative treatment approaches. The company is part of the IDIVERSA index, launched by B3, highlighting companies committed to gender and racial diversity. For more information, visit: www.grupooncoclinicas.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241211008868/en/ CONTACT: Media Contacts The Menarini Group Valeria Speroni Cardi Email:pressoffice@menarini.comStemline Therapeutics, Inc. Cheya Pope Email:media@menarinistemline.comGlobal Brand Communication MEDSIR: Sergio Aguilar Global Brand & Communication Director +34 674 82 87 24 sergio.aguilar@medsir.orgEduardo Martín Espallargas Global Communication & Marketing Manager +34 634 835 389 Eduardo.martin@medsir.orgCarles Berloso Cortés International PR & Comms +34 677 49 75 23 carles.berloso@medsir.org KEYWORD: TEXAS SPAIN NORTH AMERICA UNITED STATES EUROPE ITALY INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: The Menarini Group Copyright Business Wire 2024. PUB: 12/11/2024 06:35 PM/DISC: 12/11/2024 06:35 PM http://www.businesswire.com/news/home/20241211008868/en

The long sports-filled Thanksgiving weekend is a time when many Americans enjoy gathering with friends and family for good food, good company and hopefully not too much political conversation. Also on the menu — all the NFL and college sports you can handle. Here's a roadmap to one of the biggest sports weekends of the year, with a look at marquee games over the holiday and how to watch. All times are in EST. All odds are by BetMGM Sportsbook. • NFL: There is a triple-header lined up for pro football fans. Chicago at Detroit, 12:30 p.m., CBS: Rookie quarterback Caleb Williams and the Bears go against the Lions, who are one of the favorites to reach the Super Bowl in February. Lions favored by 10. New York at Dallas, 4:30 p.m., Fox: The Giants and Cowboys are both suffering through miserable seasons and are now using backup quarterbacks for different reasons. But if Dallas can figure out a way to win, it will still be on the fringe of the playoff race. Cowboys favored by 3 1/2. Miami at Green Bay, 8:20 p.m., NBC/Peacock: The Packers stumbled slightly out of the gate but have won six of their past seven games. They'll need a win against Miami to try to keep pace in the NFC North. Packers favored by 3. • College Football: Memphis at No. 18 Tulane, 7:30 p.m., ESPN. If college football is your jam, this is a good warmup for a big weekend. The Tigers try to ruin the Green Wave’s perfect record in the American Athletic Conference. Tulane is favored by 14. Kansas City Chiefs quarterback Patrick Mahomes works in the pocket against the Carolina Panthers during the first half of Sunday's game in Charlotte, N.C. • NFL: A rare Friday showdown features the league-leading Chiefs. Las Vegas at Kansas City, 3 p.m. Prime Video: The Chiefs and quarterback Patrick Mahomes are 12-point favorites over the Raiders. • College Basketball: Some of the top programs meet in holiday tournaments around the country. Battle 4 Atlantis championship, 5:30 p.m., ESPN: One of the premier early season tournaments, the eight-team field includes No. 3 Gonzaga, No. 14 Indiana and No. 24 Arizona. Rady Children's Invitational, 6 p.m., Fox: It's the championship game for a four-team field that includes No. 13 Purdue and No. 23 Mississippi. • College Football: There is a full slate of college games to dig into. Oregon State at No. 11 Boise State, noon, Fox: The Broncos try to stay in the College Football Playoff hunt when they host the Beavers. Boise State favored by 19 1/2. Oklahoma State at No. 23 Colorado, noon, ABC: The Buffaloes and Coach Prime are still in the hunt for the Big 12 championship game when they host the Cowboys. Colorado favored by 16 1/2. Georgia Tech at No. 6 Georgia, 7:30 p.m., ABC: The Bulldogs are on pace for a spot in the CFP but host what could be a tricky game against rival Georgia Tech. Georgia favored by 19 1/2. • NBA. After taking Thanksgiving off, pro basketball returns. Oklahoma City at Los Angeles Lakers, 10 p.m., ESPN: The Thunder look like one of the best teams in the NBA's Western Conference. They'll host Anthony Davis, LeBron James and the Lakers. • College Football. There are more matchups with playoff implications. Michigan at No. 2 Ohio State, noon, Fox: The Wolverines are struggling one season after winning the national title. They could make their fan base a whole lot happier with an upset of the Buckeyes. Ohio State favored by 21. No. 7 Tennessee at Vanderbilt, noon, ABC: The Volunteers are a fairly big favorite and have dominated this series, but the Commodores have been a tough team this season and already have achieved a monumental upset over Alabama. Tennessee favored by 11. No. 16 South Carolina at No. 12 Clemson, noon, ESPN: The Palmetto State rivals are both hanging on the edge of the CFP playoff race. A win — particularly for Clemson — would go a long way toward clinching its spot in the field. Clemson favored by 2 1/2. No. 3 Texas at No. 20 Texas A&M, 7:30 p.m. ABC: The Aggies host their in-state rival for the first time since 2011 after the Longhorns joined the SEC. Texas favored by 5 1/2. Washington at No. 1 Oregon, 7:30 p.m., NBC: The top-ranked Ducks have been one of the nation’s best teams all season. They’ll face the Huskies, who would love a marquee win in coach Jedd Fisch’s first season. Oregon favored by 19 1/2. • NBA: A star-studded clash is part of the league's lineup. Golden State at Phoenix, 9 p.m., NBA TV: Steph Curry and the Warriors are set to face the Suns' Big Three of Kevin Durant, Devin Booker and Bradley Beal. • NFL: It's Sunday, that says it all. Pittsburgh at Cincinnati, 1 p.m., CBS: Joe Burrow is having a great season for the Bengals, who are struggling in other areas. They need a win to stay in the playoff race, hosting a Steelers team that's 8-3 and won five of their past six. Bengals favored by 3. Arizona at Minnesota, 1 p.m., Fox: The Cardinals are tied for the top of the NFC West while the Vikings are 9-2 and have been one of the biggest surprises of the season with journeyman Sam Darnold under center. Vikings favored by 3 1/2. Philadelphia at Baltimore, 4:25 p.m., CBS: Two of the league's most electric players will be on the field when Saquon Barkley and the Eagles travel to face Lamar Jackson and the Ravens. Ravens favored by 3. San Francisco at Buffalo, 8:20 p.m. NBC/Peacock: The 49ers try to get back to .500 against the Bills, who have won six straight. Bills favored by 7. • NBA. The best teams in the Eastern Conference meet in a statement game. Boston at Cleveland, 6 p.m., NBA TV: The defending champion Celtics travel to face the Cavs, who won their first 15 games to start the season. • Premier League: English soccer fans have a marquee matchup. Manchester City at Liverpool, 11 a.m., USA Network/Telemundo. The two top teams meet with Manchester City trying to shake off recent struggles. • Auto Racing: The F1 season nears its conclusion. F1 Qatar Grand Prix, 11 a.m., ESPN2 – It's the penultimate race of the season. Max Verstappen already has clinched his fourth consecutive season championship. Before the 2023 National Football League season started, it seemed inevitable that Bill Belichick would end his career as the winningest head coach in league history. He had won six Super Bowls with the New England Patriots and 298 regular-season games, plus 31 playoff games, across his career. Then the 2023 season happened. Belichick's Patriots finished 4-13, the franchise's worst record since 1992. At the end of the year, Belichick and New England owner Robert Kraft agreed to part ways. And now, during the 2024 season, Belichick is on the sideline. He's 26 wins from the #1 spot, a mark he'd reach in little more than two seasons if he maintained his .647 career winning percentage. Will he ascend the summit? It's hard to tell. Belichick would be 73 if he graced the sidelines next season—meaning he'd need to coach until at least 75 to break the all-time mark. Only one other NFL coach has ever helmed a team at age 73: Romeo Crennel in 2020 for the Houston Texans. With Belichick's pursuit of history stalled, it's worth glancing at the legends who have reached the pinnacle of coaching success. Who else stands among the 10 winningest coaches in NFL history? Stacker ranked the coaches with the most all-time regular-season wins using data from Pro Football Reference . These coaches have combined for 36 league championships, which represents 31.6% of all championships won throughout the history of pro football. To learn who made the list, keep reading. You may also like: Ranking the biggest NFL Draft busts of the last 30 years - Seasons coached: 23 - Years active: 1981-2003 - Record: 190-165-2 - Winning percentage: .535 - Championships: 0 Dan Reeves reached the Super Bowl four times—thrice with the Denver Broncos and once with the Atlanta Falcons—but never won the NFL's crown jewel. Still, he racked up nearly 200 wins across his 23-year career, including a stint in charge of the New York Giants, with whom he won Coach of the Year in 1993. In all his tenures, he quickly built contenders—the three clubs he coached were a combined 17-31 the year before Reeves joined and 28-20 in his first year. However, his career ended on a sour note as he was fired from a 3-10 Falcons team after Week 14 in 2003. - Seasons coached: 23 - Years active: 1969-91 - Record: 193-148-1 - Winning percentage: .566 - Championships: 4 Chuck Noll's Pittsburgh Steelers were synonymous with success in the 1970s. Behind his defense, known as the Steel Curtain, and offensive stars, including Terry Bradshaw, Franco Harris, and Lynn Swann, Noll led the squad to four Super Bowl victories from 1974 to 1979. Noll's Steelers remain the lone team to win four Super Bowls in six years, though Andy Reid and Kansas City could equal that mark if they win the Lombardi Trophy this season. Noll was elected to the Pro Football Hall of Fame in 1993, two years after retiring. His legacy of coaching success has carried on in Pittsburgh—the club has had only two coaches (Bill Cowher and Mike Tomlin) since Noll retired. - Seasons coached: 21 - Years active: 1984-98, 2001-06 - Record: 200-126-1 - Winning percentage: .613 - Championships: 0 As head coach of Cleveland, Kansas City, Washington, and San Diego, Marty Schottenheimer proved a successful leader during the regular season. Notably, he was named Coach of the Year after turning around his 4-12 Chargers team to a 12-4 record in 2004. His teams, however, struggled during the playoffs. Schottheimer went 5-13 in the postseason, and he never made it past the conference championship round. As such, the Pennsylvania-born skipper is the winningest NFL coach never to win a league championship. - Seasons coached: 25 - Years active: 1946-62, '68-75 - Record: 213-104-9 - Winning percentage: .672 - Championships: 7 The only coach on this list to pilot a college team, Paul Brown, reached the pro ranks after a three-year stint at Ohio State and two years with the Navy during World War II. He guided the Cleveland Browns—named after Brown, their first coach—to four straight titles in the fledgling All-America Football Conference. After the league folded, the ballclub moved to the NFL in 1950, and Cleveland continued its winning ways, with Brown leading the team to championships in '50, '54, and '55. He was fired in 1963 but returned in 1968 as the co-founder and coach of the Cincinnati Bengals. His other notable accomplishments include helping to invent the face mask and breaking pro football's color barrier . - Seasons coached: 33 - Years active: 1921-53 - Record: 226-132-22 - Winning percentage: .631 - Championships: 6 An early stalwart of the NFL, Curly Lambeau spent 29 years helming the Green Bay Packers before wrapping up his coaching career with two-year stints with the Chicago Cardinals and Washington. His Packers won titles across three decades, including the league's first three-peat from 1929-31. Notably, he experienced only one losing season during his first 27 years with Green Bay, cementing his legacy of consistent success. Born in Green Bay, Lambeau co-founded the Packers and played halfback on the team from 1919-29. He was elected to the Hall of Fame as a coach and owner in 1963, two years before his death. You may also like: Countries with the most active NFL players - Seasons coached: 26 - Years active: 1999-present - Record: 267-145-1 - Winning percentage: .648 - Championships: 3 The only active coach in the top 10, Andy Reid has posted successful runs with both the Philadelphia Eagles and Kansas City. After reaching the Super Bowl once in 14 years with the Eagles, Reid ratcheted things up with K.C., winning three titles since 2019. As back-to-back defending champions, Reid and Co. are looking this season to become the first franchise to three-peat in the Super Bowl era and the third to do so in NFL history after the Packers of 1929-31 and '65-67. Time will tell if Reid and his offensive wizardry can lead Kansas City to that feat. - Seasons coached: 29 - Years active: 1991-95, 2000-23 - Record: 302-165 - Winning percentage: .647 - Championships: 6 The most successful head coach of the 21st century, Bill Belichick first coached the Cleveland Browns before taking over the New England Patriots in 2000. With the Pats, Belichick combined with quarterback Tom Brady to win six Super Bowls in 18 years. Belichick and New England split after last season when the Patriots went 4-13—the worst record of Belichick's career. His name has swirled around potential coaching openings , but nothing has come of it. Belichick has remained in the media spotlight with his regular slot on the "Monday Night Football" ManningCast. - Seasons coached: 33 - Years active: 1963-95 - Record: 328-156-6 - Winning percentage: .677 - Championships: 2 The winningest head coach in NFL history is Don Shula, who first coached the Baltimore Colts (losing Super Bowl III to Joe Namath and the New York Jets) for seven years before leading the Miami Dolphins for 26 seasons. With the Fins, Shula won back-to-back Super Bowls in 1972 and 1973, a run that included a 17-0 season—the only perfect campaign in NFL history. He also coached quarterback great Dan Marino in the 1980s and '90s, but the pair made it to a Super Bowl just once. Shula was inducted into the Hall of Fame in 1997. Story editing by Mike Taylor. Copy editing by Robert Wickwire. Photo selection by Lacy Kerrick. You may also like: The 5 biggest upsets of the 2023-24 NFL regular season Get local news delivered to your inbox!TOKYO (AP) — Troops surround South Korea's parliament overnight when the president declares martial law. He accuses pro-North Korean forces of plotting to overthrow one of the world’s most vibrant democracies. Lawmakers voice outrage and vote to end the declaration, and the president lifts the decree before daybreak. President Yoon Suk Yeol spread fear and confusion through South Korea overnight by issuing his sudden edict late Tuesday, the first martial law declaration since more than four decades ago when the country was controlled by a dictatorship. The declaration, the rushed vote by lawmakers to overturn it and the president's lifting of martial law soon afterward were moments of high drama for an unpopular leader who has struggled with political deadlock in an opposition-dominated parliament and scandals involving him and his wife. While there was no direct evidence presented, Yoon raised the specter of North Korea as a destabilizing force. Yoon has long maintained that a hard line against the North is the only way to stop Pyongyang from following through on its nuclear threats against Seoul. Amid the surreal scenes of troops massing around parliament, here are some things to know as this story unfolds: Immediately after Yoon's declaration the military chief called in key commanders for talks. South Korean troops set up barricades and then made their way into parliament. The leader of the main opposition, which controls parliament, ordered lawmakers to return to the building, where they eventually voted to lift the declaration of martial law. Yoon lifted the martial law decree around 4:30 a.m. during a Cabinet meeting. Yoon's declaration had been accompanied by an accusation that the opposition was engaged in “anti-state activities plotting rebellion.” But he did not explain what that means, and provided no specific evidence. The vague statement is reminiscent of the heavy-handed tactics of the South Korean dictatorships that ended in the late 1980s. A series of strongmen repeatedly invoked North Korea when struggling to control domestic dissidents and political opponents. The opposition lambasted Yoon's move as un-democratic. Opposition leader Lee Jae-myung, who narrowly lost to Yoon in the 2022 presidential election, called Yoon’s announcement “illegal and unconstitutional.” But the sudden declaration was also opposed by the leader of Yoon's own conservative party, Han Dong-hoon, who called the decision “wrong” and vowed to “stop it with the people.” “The people will block the president’s anti-constitutional step. The military must be on the side of the public in any case. Let’s resolutely oppose it,” Kim Dong Yeon, the opposition party governor of Gyeonggi province, which surrounds Seoul, wrote on X. Average South Koreans were in shock. Social media was flooded with messages expressing surprise and worry over Yoon’s announcement. “Martial law? I thought it was deepfake content, but is it really a martial law decree?,” one X user wrote. “I first thought about a war with North Korea when he said he would impose a martial law,” another X user wrote. There were quick claims that the emergency declaration was linked to Yoon’s political struggles. His approval rating has dropped, and he has had little success in getting his policies adopted by a parliament that has been controlled by the opposition since he took over in 2022. Conservatives have said the opposition moves are political revenge for investigations into the opposition leader, who is seen as the favorite for the next presidential election in 2027. Just this month, Yoon denied wrongdoing in an influence-peddling scandal involving him and his wife. The claims have battered his approval ratings and fueled attacks by his rivals. The scandal centers on claims that Yoon and first lady Kim Keon Hee exerted inappropriate influence on the conservative ruling People Power Party to pick a certain candidate to run for a parliamentary by-election in 2022 at the request of Myung Tae-kyun, an election broker and founder of a polling agency who conducted free opinion surveys for Yoon before he became president . Yoon has said he did nothing inappropriate. South Korea became a democracy only in the late 1980s, and military intervention in civilian affairs is still a touchy subject. During the dictatorships that emerged as the country rebuilt from the destruction of the 1950-53 Korean War, leaders occasionally proclaimed martial law that allowed them to station combat soldiers, tanks and armored vehicles on streets or in public places to prevent anti-government demonstrations. Such scenes are unimaginable for many today. The dictator Park Chung-hee, who ruled South Korea for nearly 20 years before he was assassinated by his spy chief in 1979, led several thousand troops into Seoul in the early hours of May 16, 1961, in the country’s first successful coup. During his rule, he occasionally proclaimed martial law to crack down on protests and jail critics. Less than two months after Park Chung-hee’s death, Maj. Gen. Chun Doo-hwan led tanks and troops into Seoul in December 1979 in the country’s second successful coup. The next year, he orchestrated a brutal military crackdown on a pro-democracy uprising in the southern city of Gwangju, killing at least 200 people. In the summer of 1987, massive street protests forced Chun’s government to accept direct presidential elections. His army buddy Roh Tae-woo, who had joined Chun’s 1979 coup, won the election held later in 1987 thanks largely to divided votes among liberal opposition candidates. AP writers Kim Tong-hyung and Hyung-jin Kim contributed to this story.

Elon Musk hits out at Albanese government’s ‘backdoor’ social media ban

Serve Robotics president & COO sells $11,957 in stockNew York, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (Nasdaq: NVAC) (the “Company”) announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). This notification has no immediate effect on the listing of the Company’s shares on Nasdaq. However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company’s securities will be subject to delisting from Nasdaq. Under Nasdaq rules, the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 days from the prescribed due date for filing the Form 10-Q to regain compliance. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The Company is working diligently and expects to file its Form 10-Q within the 60-day period described above, which would eliminate the need for the Company to submit a formal plan to regain compliance. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. About NorthView Acquisition Corporation NorthView Acquisition Corporation is a blank check company incorporated in the State of Delaware for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Forward Looking Statements This press release contains statements that constitute “forward-looking statements”. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and final prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Company Contacts: Fred Knechtel Fredknechtel@hotmail.com 631 987-8921President-elect Donald Trump’s lawyers formally asked a judge Monday to throw out his hush money criminal conviction, arguing continuing the case would present unconstitutional “disruptions to the institution of the Presidency.“ File video above: Former President Donald Trump found guilty in hush money trial In a filing made public Tuesday, Trump’s lawyers told Manhattan Judge Juan M. Merchan that dismissal is warranted because of the “overwhelming national mandate granted to him by the American people on November 5, 2024.” “Wrongly continuing proceedings in this failed lawfare case disrupts President Trump’s transition efforts,” the attorneys continued, before citing the “overwhelming national mandate granted to him by the American people on November 5, 2024.” They also cited President Joe Biden’s recent pardon of his son, Hunter Biden, who had been convicted of tax and gun charges. “President Biden asserted that his son was ‘selectively, and unfairly, prosecuted,’ and ‘treated differently,’" Trump’s legal team wrote. The Manhattan district attorney, they claimed, had engaged in the type of political theater "that President Biden condemned.” Prosecutors will have until Dec. 9 to respond. They have said they will fight any efforts to dismiss the case but have indicated a willingness to delay the sentencing until after Trump’s second term ends in 2029. In their filing Monday, Trump's attorneys dismissed the idea of holding off sentencing until Trump is out of office as a “ridiculous suggestion.” Following Trump’s election victory last month, Merchan halted proceedings and indefinitely postponed his sentencing , previously scheduled for late November, to allow the defense and prosecution to weigh in on the future of the case. He also delayed a decision on Trump’s prior bid to dismiss the case on immunity grounds. Trump has been fighting for months to reverse his conviction on 34 counts of falsifying business records to conceal a $130,000 payment to porn actor Stormy Daniels to suppress her claim that they had sex a decade earlier. He says they did not and denies any wrongdoing. Taking a swipe at Bragg and New York City, as Trump often did throughout the trial, the filing argues that dismissal would also benefit the public by giving him and “the numerous prosecutors assigned to this case a renewed opportunity to put an end to deteriorating conditions in the City and to protect its residents from violent crime.” Clearing Trump, the lawyers added, would also allow him to “to devote all of his energy to protecting the Nation.” The defense filing was signed by Trump lawyers Todd Blanche and Emil Bove, who represented Trump during the trial and have since been selected by the president-elect to fill senior roles at the Justice Department. A dismissal would erase Trump’s historic conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office. Trump takes office Jan. 20 . Merchan hasn’t set a timetable for a decision. A dismissal would erase Trump’s historic conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office. Merchan could also decide to uphold the verdict and proceed to sentencing, delay the case until Trump leaves office, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court or choose some other option. Prosecutors had cast the payout as part of a Trump-driven effort to keep voters from hearing salacious stories about him. Trump’s then-lawyer Michael Cohen paid Daniels. Trump later reimbursed him, and Trump’s company logged the reimbursements as legal expenses — concealing what they really were, prosecutors alleged. Trump has pledged to appeal the verdict if the case is not dismissed. He and his lawyers said the payments to Cohen were properly categorized as legal expenses for legal work. A month after the verdict, the Supreme Court ruled that ex-presidents can’t be prosecuted for official acts — things they did in the course of running the country — and that prosecutors can’t cite those actions to bolster a case centered on purely personal, unofficial conduct. Trump’s lawyers cited the ruling to argue that the hush money jury got some improper evidence, such as Trump’s presidential financial disclosure form, testimony from some White House aides and social media posts made during his first term. Prosecutors disagreed and said the evidence in question was only “a sliver” of their case. If the verdict stands and the case proceeds to sentencing, Trump’s punishments would range from a fine to probation to up to four years in prison — but it’s unlikely he’d spend any time behind bars for a first-time conviction involving charges in the lowest tier of felonies. Because it is a state case, Trump would not be able to pardon himself once he returns to office. Presidential pardons apply only to federal crimes.New Jersey drones are perplexing the FBI, the Office of Homeland Security, and state police